武田薬品 presented the results of the Phase 2/3 IgGNITE trial of investigational drug TAK-881 for primary immunodeficiency at ESID 2026. TAK-881 is being evaluated as a 20% subcutaneous immunoglobulin formulation.
武田薬品 presented the results of the Phase 2/3 IgGNITE trial of investigational drug TAK-881 for primary immunodeficiency (PID) at ESID 2026.
The study involved patients with PID and evaluated TAK-881 as a 20% solution for subcutaneous administration (SCIG 20%). The investigational data were reported.
The announcement reports the release of the trial results, but the main text does not include specific figures or conclusions.